|
Mechanismβ2-adrenergic receptor agonists |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Aug 1972 |
Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine and Ketoconazole Formulation
This study is to explore the optimization of anti-onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3-mg, 6-mg and 8-mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2-mg ketoconazole/patch) and its safety profile.
/ Unknown statusNot ApplicableIIT A Taiwan Isoflavone Multicenter Study (TIMS)
Consumption of soy-based foods is associated with a number of health benefits, including lower risk of cardiovascular disease, breast and prostate cancer, attenuated menopausal symptoms and prevention of bone loss with age.
In order to investigate the effect of isoflavone on bone mineral density (BMD) and in Taiwan women with postmenopausal osteopenia, a Taiwan Isoflavone Multicentric Enrollment Study (TIMS) is designed.
100 Clinical Results associated with Taiwan Biotech Co. Ltd.
0 Patents (Medical) associated with Taiwan Biotech Co. Ltd.
Proceedings of the International Symposium on Controlled Release of Bioactive Materials
Development of an albuterol transdermal drug delivery system
Author: Jiang, T.S. ; Cheng, C.H. ; Kuo, C.C. ; Chen, S.J.
A matrix-type albuterol transdermal delivery patch was evaluated for its suitability by in vitro skin permeation and animal toxicity studies.The system delivered the drug efficiently with good skin tolerance.
100 Deals associated with Taiwan Biotech Co. Ltd.
100 Translational Medicine associated with Taiwan Biotech Co. Ltd.